Skip to content

Rapport Therapeutics, Inc.

RAPP

CIK 0002012593

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$97.58M
−42.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.56
+24.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$88.09M
Q1 May 2026
Cash
$78.06M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
47.83M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings